Document Detail


An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
MedLine Citation:
PMID:  18445184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Omalizumab is the first licensed anti-immunoglobulin (Ig) E antibody shown to be effective for treatment of allergic (IgE-mediated) asthma. Recent international guidelines recommend omalizumab as add-on treatment to fixed dose inhaled corticosteroid (ICS) and long-acting beta(2)-agonist (LABA) combination therapy. However, omalizumab is more expensive than other current asthma treatments and health and reimbursement authorities are increasingly demanding evidence of economic benefit to support pricing and formulary listing. The aims of this article are to (i) summarize data on the human and economic burden of severe asthma, (ii) summarize the efficacy data obtained for omalizumab in clinical trials in patients with inadequately controlled severe persistent allergic asthma despite high-dose ICS plus a LABA, and (iii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A wealth of evidence exists highlighting that the health, economic and societal burden of asthma is considerable and is highly skewed towards patients with severe asthma, particularly when asthma is inadequately controlled. Omalizumab is clinically beneficial in patients with severe persistent allergic asthma despite high-dose ICS plus a LABA, particularly in a subgroup of patients who respond to therapy. In patients who respond to therapy, the cost-effectiveness of omalizumab compares well with other biologic treatments for chronic illness.
Authors:
S D Sullivan; F Turk
Related Documents :
3372884 - Patterns of evaluations of accents amongst health visitor students.
6434034 - Night workload in one health district.
23045414 - The sga-er educational intervention in adolescent health care for italian physicians: g...
2714544 - Medical advice by telephone at swedish health centres: who calls and what are the probl...
7625284 - Histological changes in the swimbladder wall of eels due to abnormal location of adults...
390264 - Impact of alcohol, drug abuse and mental health treatment on medical care utilization. ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Allergy     Volume:  63     ISSN:  1398-9995     ISO Abbreviation:  Allergy     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-04-30     Completed Date:  2008-07-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804028     Medline TA:  Allergy     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  670-84     Citation Subset:  IM    
Affiliation:
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Asthmatic Agents / economics*,  therapeutic use
Antibodies, Monoclonal / economics*,  therapeutic use
Asthma / drug therapy*,  economics,  mortality
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Drug Costs
Humans
Immunoglobulin E / immunology
Quality of Life
Randomized Controlled Trials as Topic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Antibodies, Monoclonal; 0/omalizumab; 37341-29-0/Immunoglobulin E

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review.
Next Document:  Mechanisms of asthma in Olympic athletes--practical implications.